Ethanol extract from Epimedium brevicornum attenuates left ventricular dysfunction and cardiac remodeling through down-regulating matrix metalloproteinase-2 and -9 activity and myocardial apoptosis in rats with congestive heart failure

International Journal of Molecular Medicine

Volumn 21, Issue 1, 2008, Pages 117-124

  Song, Yao Hong ^a   Li, Bao Shi ^a   Chen, Xiang Min ^a   Cai, Hui ^a  

^a NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

Author keywords

Cardiac remodeling; Congestive heart failure; Epimedium; Matrix metalloproteinase; Myocardial apoptosis

Indexed keywords

ALCOHOL; ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; EPIMEDIUM BREVICORNUM EXTRACT; EPIMEDIUM EXTRACT; GELATINASE; GELATINASE A; GELATINASE B; ISOPRENALINE; METOPROLOL TARTRATE; NORADRENALIN; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEGENERATION; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG ISOLATION; DRUG MECHANISM; ENZYME ACTIVITY; EPIMEDIUM; EPIMEDIUM BREVICORNUM; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CELL; HEART RATE; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; MALE; MORPHOMETRICS; NONHUMAN; NORADRENALIN BLOOD LEVEL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; RAT; SOLVENT EXTRACTION; SYSTOLIC BLOOD PRESSURE;

EID: 38949214337     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.21.1.117     Document Type: Article

References (48)

1. van Zwieten PA: Drug treatment of congestive heart failure. Semin Cardiothorac Vasc Anesth 7: 13-17, 2003.
2. Jugdutt BI: Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 108: 1395-1403, 2003.
3. Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, Levick SP and Janicki JS: The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 30: 604-610, 2006.
4. Dhalla NS, Dent MR, Tappia PS, Sethi R, Barta J and Goyal RK: Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Ther 11: 31-45, 2006.
5. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL and Crumbley AJ: A matrix metalloproteinase induction/ activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102: 1944-1949, 2000.
6. Creemers EEJM, Cleutjens JPM, Smits JFM and Daemen MJAP: Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89: 201-210, 2001.
7. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TMA, Coker ML, Etoh T and Spinale FG: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103: 2303-2309, 2001.
8. Dixon IM, Ju H, Jassal DS and Peterson DJ: Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol Cell Biochem 165: 31-45, 1996.
9. Bristow MR: Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 80: 26-40, 1997.
10. Gao SQ, Fu DX and Zhang HM: Progress in the prevention and cure of osteoporosis by Epimedium and its prescription. China J Chin Materia Medica 24: 249-251, 1999 (In Chinese).
11. Han B and Yang JS: Pharmacological research of Epimedium. Chin Trad Herbal Drugs 31: 873-875, 2000 (In Chinese).
12. Ye LK and Chen JM: Advances in study on pharmacological effects of epimedium. China J Chin Materia Medica 26: 293-295, 2001 (In Chinese).
13. Huang XL, Wang W and Zhou YW: Protective effect of epimedium flavonoids injection on experimental myocardial infarction rats. Zhongguo Zhong Xi Yi Jie He Za Zhi 26: 68-71, 2006.
14. Kovacevic N, Colic M, Backovic A and Doslov-Kokorus Z: Immunomodulatory effects of the methanolic extract of Epimedium alpinum in vitro. Fitoterapia 77: 561-567, 2006.
15. Lee MK, Choi YJ, Sung SH, Shin DI, Kim JW and Kim YC: Antihepatotoxic activity of icariin, a major constituent of Epimedium koreanum. Planta Med 61: 523-526, 1995.
16. Liang HR, Vuorela P, Vuorela H and Hiltunen R: Isolation and immunomodulatory effect of flavonol glycosides from Epimedium hunanense. Planta Med 63: 316-319, 1997.
17. Wu H, Lien EJ and Lien LL: Chemical and pharmacological investigations of Epimedium species: a survey. Prog Drug Res 60: 1-57, 2003.
18. Li YB, Meng FH, Lu XM and Li FM: Chemical constituents from herb of Epimedium brevicornum. Zhongguo Zhong Yao Za Zhi 30: 586-588, 2005.
19. Pan Y, Kong LD, Li YC, Xia X, Kung HF and Jiang FX: Icarim from Epimedium brevicornum attenuates chronic mild stress-induced behavioral and neuroendocrinological alterations in male Wistar rats. Pharmacol Biochem Behav 87: 130-140, 2007.
20. Yap SP, Shen P, Butler MS, Gong Y, Loy CJ and Yong EL: New estrogenic prenylflavone from Epimedium brevicornum inhibits the growth of breast cancer cells. Planta Med 71: 114-119, 2005.
21. Teerlink JR, Pfeffer JM and Pfeffer MA: Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res 75: 105-113, 1994.
22. Davani S, Marandin A, Mersin N, Royer B, Kantelip, B, Hervé P, Etievent JP and Kantelip JP: Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiornyoplasty model. Circulation 108: 253-258, 2003.
23. Torimura T, Ueno, T, Kin M, Harada R, Nakamura T, Sakamoto M, Kumashiro R, Yano H, Kojiro M and Sata M: Laminin deposition to type IV collagen enhances haptotaxis, chemokinesis, and adhesion of hepatoma cells through 61-integrins. J Hepatol 35: 245-253, 2001.
24. Zhang XM, Chen J, Xia YG and Xu Q: Apoptosis of murine melanoma B16-BL6 cells induced by quercetin targeting mitochondria, inhibiting expression of PKC-α and translocating PKC-δ. Cancer Chernother Pharmacol 55: 251-262, 2005.
25. Bristow MR: 8-adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569, 2000.
26. Caulfield JB and Borg TK: The collagen network of the heart. Lab Invest 40: 364-372, 1979.
27. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sormenblick EH, Olivetti G and Anversa P: Structural basis of end-stage failure in ischernic cardiomyopathy in humans. Circulation 89: 151-163, 1994.
28. Muller-Ehmsen J and Schwinger RH: TNF and congestive heart failure: therapeutic possibilities. Expert Opin Ther Targets 8: 203-209, 2004.
29. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C and Wright TJ: Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105: 1797-1803, 2002.
30. Lage SG, Kopel L, Medeiros CCJ, Carvalho RT and Creager MA: Angiotensin II contributes to arterial compliance in congestive heart failure. Am J Physiol Heart Circ Physiol 283: H1424-H1429, 2002.
31. Cowie MR and Mendez GF: BNP and congestive heart failure. Prog Cardiovasc Dis 44: 293-321, 2002.
32. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P and Lee RT: Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99: 3063-3070, 1999.
33. Iwanaga Y, Aoyama T, Kihara Y, Onozawa Y, Yoneda T and Sasayama S: Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 39: 1384-1391, 2002.
34. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, Miwa T and Masuyama T: Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 109: 2143-2149, 2004.
35. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ and Spinale FG: Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97: 1708-1715, 1998.
36. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT and Zile MR: Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85: 364-376, 1999.
37. Chancey AL, Brower GL, Peterson IT and Janicki JS: Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105: 1983-1988, 2002.
38. Seeland U, Kouchi I, Zolk O, Itter G, Linz W and Bohm M: Effect of ramipril and furosemide treatment on interstitial remodeling in post-mfarction heart failure rat hearts. J Mol Cell Cardiol 34: 151-163, 2002.
39. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC and Kitsis RN: A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111: 1497-1504, 2003.
40. Crow MT, Mani K, Nam YJ and Kitsis RN: The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res 95: 957-970, 2004.
41. Gustafsson AB and Gottlieb RA: Bcl-2 family members and apoptosis, taken to heart. Am J Physiol Cell Physiol 292: 45-51, 2007.
42. Condorelli G, Morisco C, Stassi G, Notte A, Farina F, Sgaramella G, de Rienzo A, Roncarati R, Trimarco B and Lembo G: Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 99: 3071-3078, 1999.
43. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
44. Shizukuda Y, Buttrick PM, Geenen DL, Borczuk AC, Kitsis RN and Sonnenblick EH: B-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol 275: 961-968, 1998.
45. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG and Anversa P: Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29: 859-870, 1997.
46. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock, KL, Glembotski CC, Quintana PJ and Sabbadini RA: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 98: 2854-2865, 1996.
47. Abbate A, Bussani R, Biondi-Zoccai GGL, Rossiello R, Silvestri F, Baldi F, Biasucci LM and Baldi A: Persistent infarct-related artery occlusion is associated with an increased myocardial apoptosis at postmortem examination in humans late after an acute myocardial infarction. Circulation 106: 1051-1054, 2002.
48. Chandrashekhar Y, Sen S, Anway R and Shuros A: Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J Am Coll Cardiol 43: 295-301, 2004.